Search PubMed⌕ Search

Biomedical subjects

R Fischbach

Publications and source records attributed to R Fischbach.

At least 91 records · Page 5Linked to original sources
PubMed1987

First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs.

Ifoxetine (CGP 15 210 G) is a novel and unusual drug. It specifically and selectively blocks the 5-HT reuptake in the brain without affecting the 5-HT uptake processes in the periphery (blood platelets). In the first, open and explorative trials its tolerability and effectiveness were studied in 33 patients suffering from endogenous (n = 25) or other types of depressive disorders. In daily doses of 50 to maximally 300 mg mental condition considerably improved in 17 patients. As assessed by HAMD 7 patients out of 17 became asymptomatic (HAMD Score less than 10) whereas 10 other patients markedly improved (decrease in HAMD by greater than or equal to 50%) in the course of 3 to 4 weeks of treatment. Eleven patients improved only slightly, in 3 patients no particular change in condition could be observed and 2 patients deteriorated. This deterioration was due to psychotic decompensation after the second week of the treatment (75-100 mg/d). Apart from this, ifoxetine was well tolerated particularly at doses of 50-150 mg/day, which also appeared to be the optimal therapeutic range of doses. There were no changes in cardiovascular function or laboratory values and almost no somatic or other complaints of major concern. These preliminary results indicate that ifoxetine has antidepressant properties with possibly an advantageous side-effect profile, in comparison to other 5-HT uptake inhibitors.

Adult↗
PubMed1986

Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.

Moclobemide is a new, short-acting, reversible MAOI, preferentially affecting type A MAO. We have studied the interaction of moclobemide with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Neither tyramine capsules (50 mg) nor cheese and wine meals (65 mg tyramine) produced a significant change in blood pressure and heart rate after single or repeated doses of moclobemide in volunteers. In contrast, after 1 weeks' treatment with tranylcypromine pressure response to cheese and wine meals was severe. Blood pressure sensitivity to IV tyramine was slightly increased (1.5-2 fold; P less than 0.05 versus predrug) during moclobemide treatment in patients and volunteers. This increase was neutralised by concomitant administration of desipramine in volunteers. Amitriptyline was well tolerated when given to patients after or together with moclobemide. In conclusion, moclobemide appears relatively safe with respect to tyramine sensitivity and interaction with tricyclics.

Adult↗
PubMed1985

[Physical therapy measures in multiple sclerosis].

The physiotherapeutical treatment represents a major part of the rehabilitation. The endeavours in this respect will have to be well assigned and individually adapted to the patient. The mode of treatment will especially have to take into consideration the needs of everyday life. Therefore all functions which might be difficult to cope with for the patient or which might reduce his abilities in daily life ought to be trained already during the patient's stay in hospital. Then the careful choice of and furnishing with the necessary auxiliary devices must be planned in cooperation with the doctor, the therapeutist and the relatives. The treatment itself ought to start as early as possible. It should be continued even in phases of remission by the patient himself on the one hand, and from time to time it should be summarized in blocks of training on the other hand. The prevention of complications is to be increased by these measures and at the same time the patient is to realize the necessity of his personal engagement. The planing of the therapy must consider all possible fundamental disorders such as spasticy, palsy or plegie as well ataxy and also disorders of the bladder.

Electric Stimulation Therapy↗
PubMed1983

Hypnotic efficacy and safety of midazolam and oxazepam in hospitalized female patients.

This double-blind study in 60 hospitalized female patients comparing midazolam 15 mg, oxazepam 15 mg and placebo, demonstrated an inter-group difference in favour of midazolam with regard to efficacy. The sleep parameters of onset latency and duration were improved by midazolam. All three compounds were very well tolerated and no withdrawal symptoms were observed. Midazolam, in an oral dose of 15 mg, can thus be regarded as an effective, well-tolerated agent for the treatment of sleep disorders.

Adult↗
PubMed1983

Efficacy and safety of midazolam and vesparax in treatment of sleep disorders.

In a double-blind parallel study in which a placebo phase preceded and followed the double-blind verum phase, midazolam 15 mg and Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine) were administered to 30 female patients aged 20-76 years, suffering from insomnia secondary to neuromuscular disease. Both products were shown to be efficient hypnotics maintaining a constant level of effect. Midazolam proved to be better tolerated and, in contrast to Vesparax, did not cause hangover, nor did rebound phenomena ensue after its withdrawal.

Adult↗
PubMed1979

Maprotiline in adult depressed patients. A study of the relation between clinical efficacy and serum concentrations after repeated intravenous and peroral administration.

Maprotiline was administered initially i.v. and then p.o. to 15 adult depressive in-patients daily for three weeks in various dosages. Serum concentrations were monitored in an attempt to find a correlation to clinical response. The steady-state serum concentration attained is independent of the dosage administered. The results suggest that patients who maintain a high serum concentration will show a better therapeutic response to the drug. In 11 out of 14 patients evaluated after three weeks of daily maprotiline therapy the clinical response could be described as excellent or very good. The drug was well tolerated when given by either route.

Administration, Oral↗
PubMed1977

[Enterogenous cyst of the spinal cord associated with mucomyelia (author's transl)].

A woman of 22 years developed heavy pain in the neck and arms with weakness and paresthesia. She died two days after a myelography which was normal. At autopsy an enterogenous extra- and intra-medullary cyst of the cervical cord (C3, C4) was found. In addition the cervical cord apart from the cyst and the uppermost thoracic cord presented central clefts which were filled with mucilage. These findings are named mucomyelia and have not been reported previously.

Cysts↗
PubMed1975

[Changes in imipramine induced noradrenaline potentiation by varying activity of gastric juice under oral medication].

From the serial studies on imipramine dependent noradrenaline (NA) rise at different values of gastric acid with 336 registrations of blood pressure, it follows that a lawful relation exists between imipramine absorption and gastric juice acidity. At pH values of 3.5--6.0 a distinct decreased absorption of orally supplied imipramine was stated. After changing the pH value by acid substitution, a full absorption is reached. This state seems to be of special practical importance in the treatment of depression with thymoleptics.

Achlorhydria↗